U.S. Markets closed

Edesa Biotech, Inc. (EDSA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.74+0.36 (+4.88%)
At close: 4:00PM EDT

Edesa Biotech, Inc.

100 Spy Court
Markham, ON L3R 5H6
289 800 9600

Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Dr. Pardeep Nijhawan FRCPC, M.D.CEO, Company Sec. & Director165.15kN/A1971
Dr. Michael J. Brooks M.B.A., Ph.D.Pres259.91kN/A1978
Ms. Kathi Niffenegger CPA, CPAChief Financial Officer143.53kN/A1957
Mr. Gary KoppenjanVP of Investor Relations & CommunicationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the development and advancement of treatments for dermatological and gastrointestinal indications. Its lead product candidate is EB01, a non-steroidal anti-inflammatory molecule to treat chronic allergic contact dermatitis. Edesa Biotech, Inc. has a collaborative research project with the National Research Council of Canada to develop novel immunotherapies for vitiligo, as well as other indications; and Light Chain Bioscience for the development and commercialization of two Phase 2-ready biologic drug candidates for various therapeutic, prophylactic, and diagnostic applications. The company was founded in 2015 and is headquartered in Markham, Canada.

Corporate Governance

Edesa Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.